Scarica l'app Stockscreener
19.76
0.25%
0.05
Dopo l'orario di chiusura:
19.76
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GPCR Giù?
Forum
Previsione
Structure Therapeutics Inc Adr Borsa (GPCR) Ultime notizie
Obesity Drug Developer Structure Therapeutics to Present at Major Healthcare Conferences in September - Stock Titan
Layoff Tracker: Novartis Continues Cutting Spree With 58 Sacked in New Jersey - BioSpace
American Century Companies Inc. Has $8.83 Million Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Invesco Ltd. Boosts Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Analyzing Leap Technology (OTCMKTS:LPTC) and Molina Healthcare (NYSE:MOH) - Defense World
Promotora de Informaciones (OTCMKTS:PRISY) Trading 20.3% Higher – Still a Buy? - Defense World
ArcelorMittal South Africa (OTCMKTS:AMSIY) Trading Down 23.2% – What’s Next? - Defense World
Enterprise Group (TSE:E) Given a C$2.42 Price Target at Fundamental Research - Defense World
Culp (CULP) to Release Quarterly Earnings on Wednesday - Defense World
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Buy” by Brokerages - Defense World
Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints - Bergen Record
Analysts’ Top Healthcare Picks: Outlook Therapeutics (OTLK), Pfizer (PFE) - The Globe and Mail
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Protara Therapeutics (TARA), Annexon Biosciences (ANNX) and Agilent (A) - The Globe and Mail
Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform - MarketScreener
This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors - The Motley Fool
Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity - PR Newswire
Structure Therapeutics’ SWOT analysis: oral GLP-1 stock faces pivotal phase - Investing.com
SEED Therapeutics Named Finalist for 2025 Prix Galien USA 'Best Start-Up” Award - The Manila Times
Can Structure Therapeutics’ (GPCR) Aggressive Funding Moves Accelerate Its Obesity Drug Ambitions? - Yahoo Finance
ABSSSI Pipeline 2025: Detailed Clinical Trials - openPR.com
Up 23% to 132%, There's Still Time to Buy These 3 Stocks - The Globe and Mail
Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules - Stock Titan
FY2025 EPS Estimates for GPCR Lowered by Cantor Fitzgerald - Defense World
William Blair Has Bearish Forecast for GPCR Q3 Earnings - Defense World
FY2025 EPS Estimates for GPCR Decreased by HC Wainwright - Defense World
Leerink Partnrs Has Negative Forecast for GPCR Q3 Earnings - Defense World
Leerink Partnrs Issues Negative Outlook for GPCR Earnings - Defense World
PepGen Inc.’s Promising Clinical Developments and Strategic Advancements Earn a Buy Rating - TipRanks
Why Is Everyone Talking About UnitedHealth Group Stock? - The Globe and Mail
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors - AOL.com
Buy Rating on ACADIA Pharmaceuticals Driven by Daybue’s Sales Growth and Market Expansion - TipRanks
High demand expected for new daily weight loss pill - inkl
Lilly's obesity pill lags Novo's Wegovy injection in key trial - Reuters
Structure Therapeutics (GPCR) to Release Quarterly Earnings on Thursday - Defense World
Structure Therapeutics Reports Q2 2025 Financial Results - TipRanks
Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights - The Manila Times
The GLP-1 Arms Race: Emerging Innovators and Capital Efficiency in the Obesity Drug Gold Rush - AInvest
Oral GLP-1 Drug Developer Structure Therapeutics Advances Multiple Obesity Trials with $786M War Chest - Stock Titan
Structure Therapeutics Inc ADR (GPCR) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Eli Lilly & Co (LLY) and Avantor (AVTR) - The Globe and Mail
2 Beaten-Down Stocks With Incredible Upside Potential - AOL.com
Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Eli Lilly & Co (LLY) and Bausch + Lomb Corporation (BLCO) - The Globe and Mail
Chefs’ Warehouse (NASDAQ:CHEF) Reaches New 52-Week High After Better-Than-Expected Earnings - Defense World
Brokerages Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Target Price at $76.17 - Defense World
Brookfield (NYSE:BN) Upgraded at National Bank Financial - Defense World
Camden National (NASDAQ:CAC) Stock Price Down 7.6% Following Weak Earnings - Defense World
Century Lithium (OTC:CYDVF) Shares Down 2.6% – What’s Next? - Defense World
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Shares Down 0.9% – Here’s What Happened - Defense World
HCM Acquisition (NASDAQ:HCMA) Stock Price Down 3.4% – Here’s Why - Defense World
DeFi Technologies (OTC:DEFTF) Trading 20% Higher – What’s Next? - Defense World
GCM Grosvenor (NASDAQ:GCMGW) Trading Up 1.1% – Should You Buy? - Defense World
Encore Capital Group (NASDAQ:ECPG) & Manhattan Bridge Capital (NASDAQ:LOAN) Critical Review - Defense World
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioNTech SE (BNTX) and Galapagos (GLPG) - The Globe and Mail
Obesity Clinical Trials, Companies, Therapeutic Assessment, - openPR.com
Analysts Are Bullish on These Healthcare Stocks: Thermo Fisher (TMO), Viking Therapeutics (VKTX) - The Globe and Mail
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):